— Know what they know.
Not Investment Advice

XLRN NASDAQ

Acceleron Pharma Inc.
1W: +3.3% 1M: +2.9% 3M: +42.9% 1Y: +61.1% 3Y: +247.6% 5Y: +368.6%
$178.75
Last traded 2021-11-19 — delisted
NASDAQ · Healthcare · Biotechnology

Cash Flow Trends

Operating Cash Flow
-$130M -38.9% ▼
Capital Expenditures
$4M -27.9% ▼
5Y CAGR: +34.4%
Free Cash Flow
-$135M -38.6% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$433M +362.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2016FY2017FY2018FY2019FY2020
— Operating Activities —
Net Income-$57M-$108M-$119M-$125M-$166M
Depreciation & Amort.$2M$3M$4M$4M$4M
Stock-Based Comp.$19M$28M$25M$23M$30M
Change in Working Capital$34M$138M$19M$129M$417M
Other Non-Cash Items-$42M-$137M-$23M-$125M-$415M
Operating Cash Flow-$45M-$77M-$95M-$94M-$130M
— Investing Activities —
Capital Expenditures-$3M-$4M-$3M-$3M-$4M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$218M-$180M-$74M-$395M-$238M
Investment Sales$113M$120M$199M$327M$268M
Other Investing$0$0$0$0$0
Investing Cash Flow-$109M-$64M$123M-$71M$26M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$147M$220M$16M$259M$538M
Financing Cash Flow$147M$220M$16M$259M$538M
Net Change in Cash-$7M$79M$44M$94M$433M
Cash End of Period$21M$100M$146M$239M$673M
Free Cash Flow-$48M-$81M-$97M-$97M-$135M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms